^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR1OP2 (FGFR1 Oncogene Partner 2)

    i
    Other names: FGFR1OP2, FGFR1 Oncogene Partner 2, Fibroblast Growth Factor Receptor 1 Oncogene Partner 2, Wound Inducible Transcript 3.0, HSPC123-Like, WIT3.0
    3years
    FGFR1OP2 Promotes Proliferation and Survival of Myeloma Cells and Is a Potential Therapeutic Target (ASH 2022)
    Furthermore, Bortezomib(Bor)-induced apoptosis of MM cells was significantly increased when FGFR1OP2 expression was suppressed (Fig.1c)...We performed Western Blot to validate these results, and found expression of YAP1 decreased while MST1/2 increased in FGFR1OP2-knockdown cells (Fig.1c). This suggests that the FGFR1OP2 promotes MM cell growth and anti-apoptosis through Hippo signaling pathway.Conclusion :FGFR1OP2 is critical for the proliferation and survival of MM cells through Hippo pathway and may represent a novel target for therapy.
    PARP Biomarker
    |
    FGFR1 (Fibroblast growth factor receptor 1) • YAP1 (Yes associated protein 1) • CASP3 (Caspase 3) • FGFR1OP2 (FGFR1 Oncogene Partner 2)
    |
    FGFR1 expression
    |
    bortezomib
    over3years
    Pan-Cancer Analysis on the Oncogenic Role of Programmed Cell Death 10. (PubMed, J Oncol)
    The results of our investigation demonstrate that PDCD10 has an oncogenic function in many cancer types. This study provides a reference for future research on antitumor therapeutic targets.
    Journal • IO biomarker • Pan tumor
    |
    FGFR1 (Fibroblast growth factor receptor 1) • IFNG (Interferon, gamma) • STRN (Striatin) • AURKB (Aurora Kinase B) • FGFR1OP2 (FGFR1 Oncogene Partner 2) • TGFB1 (Transforming Growth Factor Beta 1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • PPM1A (Protein Phosphatase Mg2+/Mn2+ Dependent 1A) • PPP2CA (Protein Phosphatase 2 Catalytic Subunit Alpha 2) • STK25 (Serine/Threonine Kinase 25)
    over3years
    A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Maxinovel Pty., Ltd.
    New P2 trial
    |
    FGFR1OP2 (FGFR1 Oncogene Partner 2)
    |
    FGFR1 expression
    |
    Max-40279
    almost4years
    A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=28, Recruiting, Maxinovel Pty., Ltd.
    New P1 trial • Combination therapy
    |
    FGFR1OP2 (FGFR1 Oncogene Partner 2)
    |
    FGFR1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Max-40279
    over4years
    NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia. (PubMed, Int J Mol Sci)
    We confirmed, by qRT-PCR, the overexpression of nine DEGs, selected on the bases of the diagnostic accuracy, in a local cohort of PIF patients: SPINK2, TMA7, SPCS2, CDCP1, CAPZA1, FGFR1OP2, MAN1A2, NT5C3A and SRP54. In conclusion, the integrated analysis of NUP98 mutational analysis and transcriptome profiles allowed the identification of novel putative biomarkers for the prediction of PIF in AML.
    Clinical • Journal
    |
    NUP98 (Nucleoporin 98 And 96 Precursor 2) • FGFR1OP2 (FGFR1 Oncogene Partner 2)
    |
    NUP93 mutation